Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Drug Could Treat Trio Of Deadly Parasitic Infectious Diseases

XTALKS VITALS NEWS

Sleeping sickness – or Human African trypanosomiasis – is caused by infection with the Trypanosoma brucei parasite, which is transmitted by the tsetse fly. .

Tweetables from this article:

Tweet: New drug could treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness http://ctt.ec/l4U6t+New drug could treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness.

Tweet: GNF6702 drug acts on proteasomes, which allow the parasites to break down proteins and reuse their components http://ctt.ec/yld3R+GNF6702 drug acts on proteasomes, which allow the parasites to break down proteins and reuse their components.

Share this!

August 10, 2016 | by Sarah Massey, M.Sc.

A new proteasome inhibitor drug could effectively treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness. As described in an article in the journal Nature, the researchers screened three million compounds made by pharmaceutical company Novartis, to identify the most effective, broad-spectrum antiparasitic drugs.

All three diseases are caused by similar parasites, leading the researchers to believe that a single active pharmaceutical ingredient could be able to target them all. Sleeping sickness – or Human African trypanosomiasis – is caused by infection with the Trypanosoma brucei parasite, which is transmitted by the tsetse fly.

Chagas disease is caused by the Trypansosoma cruzi parasite, which is most common in Latin America. Leishmaniasis is spread by the sandfly, and is caused by parasites of the same name. It’s estimated that 20 million people are infected by the three parasites combined, which kill 50,000 people annually.

Currently-available drugs can treat these infections, however they are expensive and require specialized equipment, such as an intravenous drip, which are often unavailable in poorer regions. The new drug identified by researchers – named GNF6702 – was successful at treating all three parasitic infections in mouse models.



“What makes it special is the fact it is targeting all three parasites. That's the first time it has been done, so it is quite special,” Dr. Elmarie Myburgh, a researcher at the University of York, told BBC News. “To me this is obviously a big deal, I'm in this field to try and make a difference, to get to a cure, and we're working hard in the hope that it gets to patients. There's been very little incentive to spend a lot of money on these diseases as they affect a very poor, and yet large, population.”

GNF6702 acts on the protein complexes, known as proteasomes, which allow the parasites to break down proteins and reuse their components. Luckily, this compound does not affect the same protein complexes found in human cells.

According to Richard Glynne, from the Genomics Institute of the Novartis Research Foundation, identifying the proteasome as a drug target was “not by design, more by serendipity.” However, Glynne told BBC News that the drug candidate could eventually be developed into three separate pharmaceuticals, each specifically designed to treat the different parasitic infections.

“It may be a single drug for all three diseases may not be the best strategy,” said Glynne. “The biology of the diseases is different. For example in sleeping sickness the parasite is in the brain, so you need a drug that gets into the brain, so there are tweaks that may be required.”

The researchers are now conducting safety studies to determine the drug’s suitability for human clinical trials. “This is quite an important piece of research, I'm excited by it, but there's still a long way to go,” Dr. Stephen Caddick, the director of innovation at the Wellcome Trust research charity, told BBC News.


Keywords: Drug Target, Parasite, Infectious Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.